N. P. Matiytsiv, K. A. Dronska, N. M. Artymovych, A. M. Makarenko, Ya. I. Chernik



It was found that Cerebral medicine has a therapeutic effect on aging of D. melanogaster individuals with neurodegeneration caused by altered functioning of swiss cheese gene (sws). After Сerebral treatment survival of old mutants swsolfE. was improved. Comparison of brain tissue histological sections of twenty days old males grown on standard nutrient medium and the medium with C. still showed manifestation of the mutant phenotype after application of the drug. However, penetrance of the neurodegenerative phenotype decreased by 10 % and this change correlated with an increase in the viability of aging individuals. We have created a functional knockout of sws gene in glial cells using Gal4-UAS system to test the effect of the drug in the conditions of shortage sws in glial cells. Genotype of such individual was Repo-Gal4>UAS-sws-RNAi. After analysis of these flies, we found specific pathology of glial phenotype, namely: considerable vacuolization in brain tissue in the region of the transition lamina to retina and medulla. In individuals with functional knockout of sws in glia, size of neurodegeneration area decreased by 34.5 % after Cerebral treatment, and 28.4 % in case of using its low molecular weight fraction. No significant differences in the effects of Cerebral and its low molecular weight fraction were found. Our results allow to conclude that the active component of C is its low molecular weight fraction. This drug may be effective in treatment of brain pathologies with a primary damage of glial cells.


neurodegeneration, Drosophila melanogaster, swiss cheese, Gal4-UAS functional inactivation, Cerebral


1. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement, 2012; 8: 131-168.

2. Brand A.H., Perimon N. Targeted Gene Expression as a Means of Altering Cell Fates and Generating Dominant Phenotypes. Development, 1993; 118: 401-415.

3. Cauchi R. J., van den Heuvel M. The fly as a model for neurodegenerative diseases: is it worth the jump? Neurodegener Dis, 2006; 6: 338-356.

4. Chad M., Artymovych N., Makarenko O., Matiytsiv N. Effects of Mitochondrin-2 on the Dynamics of Degeneration of Brain Tissues in Drosophila with an Altered Function of the swiss cheese Gene. Neurophysiology, 2014; 6: 455-460.

5. Chen N., Yang M., Guo J. et al. Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews, 2013; 1.

6. Cicchetti F., Barker R.A. The glial response to intracerebrally delivered therapies for neurodegenerative disorders: is this a critical issue? Frontiers in Pharmacology, 2014; 5.

7. Cummings J., Morstorf T., Zhong K. Alzheimer's Research & Therapy, 2014; 6(37)10. Available at: (Accessed 3 July 2014).
PMid:25024750 PMCid:PMC4095696

8. Glynn P. Axonal degeneration and neuropathy target esterasen. Arh. Hig. Rada. Toksikol. 2007; 58: 355-358.

9. Glynn P., Holton J., Nolan C. et al. Neuropathy target esterase: immunolocalization to neuronal cell bodies and axons. Neurosci, 1998; 83: 295-302.

10. Heisenberg M., Bohl K. Isolation of anatomical brain mutants of Drosophila by histological means. Naturforsch, 1979; 34: 143-147.

11. Kasai Y., Cagan R. Drosophila as a tool for personalized medicine: a primer. Per Med, 2010; 7: 621-632.
PMid:21977050 PMCid:PMC3184507

12. Kretzschmar D., Hasan G., Sharma S. et al. The swiss cheese mutant cause glial hyperwrapping and brain degeneration in Drosophila. J. Neurosci, 1997; 17: 7425-7432.

13. Lee S., Bang J., Lee W., Cho K. Evidence-Based Complementary and Alternative Medicine. 2014; Available at: (Accessed 26 March 2014).
PMid:24790636 PMCid:PMC3984789

14. Lotti M. The pathogenesis of organophosphate polyneuropathy. Crit. Rev. Toxicol, 1992; 21: 465-487.

15. Lucas B., Pinkernelle J., Fansa H., Keilhoff G. Effects of cerebrolysin on rat Schwann cells in vitro. Acta Histochem, 2014; 116: 820-830.

16. Makarenko A.N., Vasil'eva I.G. Neuroactivating mechanism of action of the new trophinotropic drug cerebral. Eksperimental'naia i Klinicheskaia Farmakologiia. 2004; 67: 12-15.

17. Matiytsiv N., Chad M., Trush O. et al. Influence of the Mitohondrin-2 preparation on neurodegenerative phenotype swiss cheese Drosophila melanogaster mutants. Clinical & Experimental Pathology, 2011; 37: 158-161.

18. Mohylyak I., Matiytsiv N., Chernyk Ya. The influence of tissue specific inhibition of sws gene expression on Drosophila melanogaster compound eye formation. Visnyk of the Lviv Univer. Ser. Biol, 2013; 62: 117-125.

19. Mühlig-Versen M., da Cruz A. B., Tschäpe J. et al. Loss of Swiss cheese / neuropathy target esterase activity causes disruption of phosphatidylcholine homeostasis and neuronal and glial death in adult Drosophila. J. Neurosci, 2005; 25: 2865-2873.
PMid:15772346 PMCid:PMC1182176

20. Rockenstein E., Ubhi K., Trejo M. et al. CerebrolysinTM efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure. BMC Neuroscience, 2014;15; 90: doi:10.1186/1471-2202-15-90.
PMid:25047000 PMCid:PMC4122761

21. Shcherbata G.R., Matiytsiv N.P., Chernik Ya.I., Maksymiv D.V. Chemically induced mutagenesis in Drosophila melanogaster with the purpose of mutants with brain changes obtaining. Genetica, 2004; 40: 1280-1285.

22. Thies W., Bleiler L. Alzheimer's Association: 2013 Alzheimer's disease facts and figures. Alzheimers Dement, 2013; 9: 208-245.

23. Verkhratsky А., Parpura V., Pekna M. et al. Glia in the pathogenesis of neurodegenerative diseases. Biochem. Soc. Trans, 2014; 42: 1291-1301.

24. Zaccheo O., Dinsdale D., Meacock P., Glynn P. Neuropathy target esterase and its yeast homologue degrade phosphatidylcholine to glycerophosphocholine in living cells. J. Biol. Chem, 2004; 279: 24024-24033.


  • There are currently no refbacks.

Copyright (c) 2015 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.